Data completeness
2/8 — Basic
Priority Review
RITONAVIR (ritonavir) by Cipla is 12.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ritonavir is an oral antiretroviral protease inhibitor used primarily as a pharmacokinetic booster in HIV treatment regimens, though it has expanded indications including hepatitis C, COVID-19, and tuberculosis. It works by inhibiting HIV protease and is predominantly metabolized via CYP3A. The drug is indicated for HIV-infected patients and those with acquired immune deficiency syndrome, with additional uses in managing comorbidities like hypertriglyceridemia and lipodystrophy.
Pre-Launch
Pre-launch stage with Cipla as sponsor indicates emerging commercial opportunity; team building and market preparation phases are likely active.
Mechanism of Action
12.1 Mechanism of Action Ritonavir is an antiretroviral drug [see ] . 12.2 Pharmacodynamics Cardiac Electrophysiology QTcF interval was evaluated in a randomized, placebo and active (moxifloxacin 400 mg once-daily) controlled crossover study in 45 healthy adults, with 10 measurements over 12 hours…
Worked on RITONAVIR at Cipla? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.